Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is a promising biotechnology company with a focus on precision oncology therapies for the treatment of cancer, particularly in the areas of non-CNS and CNS cancers. The company's two lead MTAP-cooperative PRMT5 inhibitors hold potential in combination with RAS inhibitors for PDAC, although management's pivot away from monotherapy is a cause for caution. Additionally, while the 1L combo strategy is a more appealing option, the company's current $3.6B market cap already reflects a promising early signal and the limited follow-up data expected in 2025 may not be enough to justify further investment at this time. Therefore, the company's stock is currently rated as Neutral with a price target of $24, reflecting potential risks of clinical and regulatory failure and potential challenges in achieving sales estimates.

Bears say

Tango Therapeutics is a biotechnology company with a focus on precision medicine for cancer treatment. While the company has promising pipeline products targeting PRMT5 and CoREST, its financials are concerning with a net loss of $45.5M in the first quarter of 2026 and only enough cash to fund operations until 2028. Additionally, the company's plans for future clinical trials and partnerships may delay the potential for meaningful revenue in the near future, leading to a negative outlook on the stock.

Tango Therapeutics (TNGX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 10 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.